Company intelligence / Profile preview

S1P Therapeutics

Blacksburg, Virginia, United Statess1ptx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is in preclinical stages with promising results showing that their lead SPNS2 inhibitors are less broadly immunosuppressive with fewer adverse events compared to other therapies targeting the S1P pathway[1][2]. They have received funding support such as a $100K grant from Virginia Innovation Partnership Corporation in late 2023 to advance their technology for inflammatory bowel disease treatment[5].

Therapeutic areas: ImmunologyNephrology
Modalities: Small molecule inhibitors targeting sphingosine 1-phosphate transporters
Industry: Biotech

Drug pipeline

1 asset

STX2310

Preclinical

Beyond the preview

Go deeper on S1P Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1P Therapeutics.

Explore the full profile